GlassScriptPhysician profile
Islam M Abujubara
NPI 1265626774
$16,691.22
in general payments reported to CMS, 2019-2025
69 companies · $3,079 in 2025
The $3,079 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,321 · 2020: $1,691 · 2021: $1,890 · 2022: $2,745 · 2023: $2,954 · 2024: $3,012 · 2025: $3,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,045.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,735.94 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Novartis Pharmaceuticals Corporation | $1,429.72 | 2019-2025 | |
| Abbvie INC. | $1,324.07 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $1,027.77 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $967.15 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Watermark Medical, INC. | $884.83 | 2020-2022 | |
| Sk Life Science, INC. | $685.83 | 2020-2025 | Xcopri |
| Biogen, INC. | $593.61 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Genentech USA, INC. | $558.42 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Pfizer INC. | $518.33 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $499.34 | 2020-2025 | Rytary, Crexont |
| Eisai INC. | $458.53 | 2019-2025 | |
| Lundbeck LLC | $439.16 | 2020-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $433.87 | 2019-2025 | Ultomiris |
| Amgen INC. | $413.84 | 2019-2024 | Uplizna |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Islam Abujubara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.